

Parkinson's Disease (PD)

A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease

Trial Status
Recruiting

Trial Runs In
3 Countries

Trial Identifier
NCT05924243 BP43176

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a multi-center, randomized, double blind, adaptive, parallel-group, placebo controlled Phase 1b study to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics of RO7486967 in participants with idiopathic PD at the early stage of the disease (modified H&Y stage #2.5) who are either treatment-naïve or on stable treatment with symptomatic therapy (levodopa and/or pramipexole, ropinirole, rotigotine).

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT05924243 BP43176
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥40 Years & ≤ 85 Years

Healthy Volunteers
No